4,4-Difluorocyclohexanecarboxylic acid:Exports & Compliance White Paper 2026

I. Executive Summary

4,4-Difluorocyclohexanecarboxylic acid, CAS 122665-97-8, is a gem-difluorinated alicyclic carboxylic acid used primarily as a medicinal-chemistry building block. Its value lies in combining a derivatizable carboxyl group with a conformationally influential CF2 center positioned across the cyclohexane ring. Discovery teams use this architecture to tune lipophilicity, polarity, metabolic stability, and three-dimensional exit vectors without introducing a long perfluoroalkyl chain.

The 2026 market is specification-led rather than commodity-led. Buyers seek gram-to-multikilogram custom synthesis, reliable stereochemical and positional-impurity control, and analytical packages that support downstream amide or ester programs. Commercial differentiation therefore depends on route knowledge, fluorination safety engineering, trace-metal and residual-reagent control, and a credible path from research-use-only material to an appropriately controlled GMP intermediate campaign.

Procurement decisions must also address fluorine-related scrutiny. This discrete gem-difluorinated cycloaliphatic is generally outside the OECD perfluoroalkyl PFAS core definition used for persistent perfluoroalkyl chains, yet broad buyer questionnaires, EU PFAS-restriction scoping, and US TSCA Section 8(a)(7) reviews may still request structural disclosure. Suppliers need substance-specific evidence on emissions, fluoride-containing waste, degradation potential, and whether any route impurity or by-product could form trifluoroacetic acid rather than relying on a simple “not PFAS” declaration.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule contains a polar, ionizable carboxylic acid and a neutral geminal difluoride on a saturated six-membered ring. This creates a compact, nonplanar building block with distinct hydrogen-bonding, dipole, and solubility behavior from cyclohexanecarboxylic acid, while preserving familiar acid-to-amide, acid-to-ester, and salt-forming chemistry for library production. The two fluorines are attached to the same ring carbon, so no stereocenter is created at C4 by the fluorination itself, but substitution patterns elsewhere on the ring can still require defined cis and trans control.

• Conformation and vector control: The electron-withdrawing CF2 center changes local bond polarization and can shift cyclohexane chair populations and substituent preferences. For medicinal chemists, the practical result is a controlled three-dimensional relationship between the acid-derived attachment point and the fluorinated face, useful when replacing flatter aromatic or more metabolically vulnerable alicyclic motifs.
• Metabolic-blocking and bioisosteric function: Strong C–F bonds at C4 can reduce oxidation at that carbon and alter neighboring hydration and enzyme recognition. The CF2 unit may serve as a carbonyl-adjacent polarity or methylene-modifying strategy, but it is not a universal carbonyl bioisostere; project teams should confirm permeability, clearance, pKa, and target binding experimentally in each scaffold.

2.2 Synthesis and Manufacturing Technologies

Commercial routes commonly start from a 4-oxocyclohexanecarboxylate or a protected equivalent, convert the ring ketone to CF2, then reveal the carboxylic acid. Process selection balances fluorination conversion against ester stability, elimination, rearrangement, and difficult-to-purge sulfur- or nitrogen-containing residues. Route scouting should define impurity fate before scale-up rather than merely maximizing isolated yield.

• Deoxyfluorination route classes: DAST-type, Deoxo-Fluor-type, and sulfur tetrafluoride-based technologies can replace the ketone oxygen with two fluorines. These are route classes, not interchangeable recipes: each has different exotherm, gas evolution, reagent decomposition, corrosion, and impurity profiles. Qualified plants use reaction calorimetry, controlled charging, compatible metallurgy or fluoropolymer linings, scrubbed vents, and defined emergency quench engineering.
• Hydrolysis, isolation, and HF control: Ester hydrolysis and crystallization can provide a robust final purge of nonpolar and colored impurities when solvent and pH windows are mapped. Any HF generated or carried through fluorination requires closed transfer, remote handling, calcium-gluconate preparedness, corrosion inspection, fluoride monitoring, and neutralization systems designed for heat release and insoluble fluoride salts. Glass contact is normally avoided where free fluoride is plausible.

2.3 Core Application Matrix

• Medicinal-chemistry building block: The acid is coupled to amines or converted into activated derivatives for structure–activity-relationship libraries. Buyers prioritize identity by NMR and high-resolution MS, assay by a stability-indicating chromatographic method, water, residual solvents, and confirmation that positional isomers or incompletely fluorinated analogues are controlled.
• Custom pharmaceutical intermediates: Once a candidate advances, CDMOs can develop a locked route, impurity reference standards, fate-and-purge knowledge, and scalable isolation. Supply remains an intermediate service; the material has no approved therapeutic indication of its own and is not a finished consumer product.
• Agrochemical and specialty discovery: Compact fluorinated carboxylates can also support crop-science and advanced-material screening. These programs require separate end-use declarations, toxicology strategies, and market-specific registrations; pharmaceutical-quality documentation does not automatically establish suitability for pesticidal or other regulated applications. Procurement teams should also confirm that the requested quantity and lead time match the intended development stage, because custom fluorination campaigns are scheduled assets rather than instant catalog inventory.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand follows fluorinated fragment use in small-molecule discovery, where sponsors increasingly request saturated, three-dimensional building blocks with interpretable metabolic effects. Catalog quantities initiate projects, but value moves quickly toward custom lots with tighter impurity limits, dependable lead times, and documentation suitable for regulatory starting-material assessment. PFAS screening has not eliminated demand; it has shifted inquiries toward transparent molecular identity, lifecycle evidence, and fluorine mass-balance questions.

3.2 Capacity Distribution and Export Flows

China and India provide broad custom-synthesis capacity and route flexibility, while European and US specialists concentrate on complex fluorination, analytical development, and sponsor-proximate GMP execution. Material typically moves from Asian research or pilot manufacture to discovery centers in North America, Europe, and Japan. Resilient programs qualify a second route or finishing site because specialized fluorinating reagents, corrosion-compatible assets, and hazardous-waste capacity—not generic reactor volume—are the true constraints.

3.3 Market Bifurcation and Pricing Dynamics

The market divides between research-use-only catalog material and sponsor-specific, fully documented campaigns. Price per kilogram reflects fluorination yield, reagent class, campaign size, analytical burden, waste treatment, and required change control. A low quotation may omit impurity synthesis, method qualification, elemental-impurity evaluation, stability, or transport classification. Buyers should compare total delivered scope and reproducibility, not nominal assay and unit price alone.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Regulatory status depends on volume, jurisdiction, supply-chain role, and intended use. A CAS listing or supplier SDS is not proof of inventory compliance. Importers must determine registration or exemption status, confirm classification from available data, and document whether the lot is RUO, a non-GMP intermediate, or part of a GMP-controlled pharmaceutical campaign.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH and CLP: EU importers should verify tonnage-triggered REACH obligations, only-representative coverage, applicable research-and-development exemptions, and a defensible CLP self-classification. Substance identity must address isomers and impurities. The SDS should align exposure controls with acid handling and any data-supported acute, irritant, or environmental hazard rather than copying a generic fluorinated-building-block profile.
• PFAS restriction scoping: The cyclic gem-difluoride generally sits outside the core long-chain perfluoroalkyl concern, but proposed EU PFAS restriction work and customer definitions can be broader than legacy regulatory lists. Buyers should request structural rationale, intentionally added fluorinated-substance declarations, analytical limits for relevant fluorinated impurities, and a documented assessment of fluoride and possible TFA-related transformation pathways.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory and reporting: US parties must establish whether the exact substance is active, exempt, or requires premanufacture review before nonexempt commercial import. TSCA Section 8(a)(7) PFAS reporting attention warrants a documented applicability analysis based on the rule's definitions, manufacture or import history, and available environmental and health information; assumptions based only on marketing terminology are inadequate.
• Pharmaceutical quality interface: Where the acid enters a regulated drug route, ICH Q11 supports justified starting-material selection and control strategy, ICH Q7 governs appropriate GMP expectations from the defined starting point, and ICH Q3D informs elemental-impurity risk assessment. FDA status is product- and application-specific; neither RUO labeling nor a high assay makes the standalone building block an approved API.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

ESG performance is dominated by fluorinating-reagent manufacture, solvent intensity, low first-pass yield, and fluoride-bearing aqueous waste. Credible suppliers report process mass intensity and waste categories at campaign level, maintain lawful hazardous-waste routes, and avoid claiming environmental safety merely because the product lacks a long perfluoroalkyl chain. Buyer ESG reviews increasingly request evidence of fluoride accountability, including neutralization, precipitation, sludge disposal, and wastewater monitoring.

5.1 Carbon Footprint and Circular Economy

Route comparison should include fluorinating-reagent equivalents, solvent recovery, cooling demand, scrubber alkali, and incineration of fluorinated residues. Scope 1–3 estimates are more useful when linked to a defined batch and allocation method. Solvent recycling may reduce footprint, but recycled streams require controls preventing cross-contamination. Thermal destruction of fluorinated vent gas or waste needs validated operating conditions and downstream HF scrubbing rather than an unqualified destruction claim.

5.2 Sustainable Sourcing and Traceability

Traceability should extend to the ketone precursor, fluorinating reagent, critical solvents, and outsourced waste contractor. Buyers increasingly audit fluoride mass balance, wastewater monitoring, occupational-health controls, and evidence against uncontrolled discharge. Supplier questionnaires should distinguish the target molecule from fluorinated processing aids and impurities, because a narrow CAS declaration can miss substances relevant to corporate PFAS policies.

VI. Supply Chain Resilience and Export Logistics

Stable supply requires realistic forecasts, campaign reservation, and dual sourcing of fluorination capability. The acid is normally shipped as a solid or concentrated controlled form, subject to the supplier's tested classification. Procurement files should connect batch CoA, SDS, origin, customs description, transport assessment, and end-use statement to the same CAS and lot.

6.1 Packaging Standards and Moisture/Contamination Control

• Primary containment: Use chemically compatible, tightly sealed inner packaging, commonly a pharmaceutical-grade polyethylene bag or fluorine-compatible bottle within a rigid outer container. Packaging qualification should assess acid compatibility, extractables risk for sensitive programs, closure integrity, and protection from humidity, dust, and foreign fibers.
• Storage and sampling: Store dry, cool, and away from incompatible bases, oxidants, and reactive metals as indicated by the SDS. Sampling under controlled humidity limits water variability. Retest dating should be supported by stability data, with transport excursions evaluated against appearance, assay, water, and impurity trend rather than automatically accepted. Dedicated sampling tools and documented line clearance help prevent cross-contamination between diverse fluorinated intermediates.

6.2 Dangerous Goods Identification and Transit Protocols

No universal UN assignment should be inferred from the name alone. The consignor must classify the tested commercial form under current ADR, IMDG, and IATA criteria, considering acidity, toxicity, and environmental data. If not regulated as dangerous goods, robust leakproof packaging and accurate customs documentation still apply. If classified, use the correct UN number, packing group, labels, shipper declaration, and trained carrier; never reuse the hazard profile of a fluorinating reagent for the finished acid.

VII. Enterprise Global Expansion Strategy Guide

Successful commercialization links molecular performance to a staged quality and compliance plan. Suppliers should offer transparent scope choices while preventing RUO material from being represented as GMP-grade. Commercial contracts should also define who owns method validation, impurity standards, and change notification, because those responsibilities determine whether a campaign can survive regulatory scrutiny later.

1. Segment RUO and GMP pathways: Define separate facilities, records, specifications, and release statements for catalog research material and sponsor-controlled campaigns. Before clinical use, agree the regulatory starting-point rationale, quality agreement, method transfer, impurity qualification, stability protocol, and audit rights.
2. Qualify fluorination capability: Audit reaction calorimetry, HF detection, scrubbers, metallurgy, maintenance, operator training, emergency response, and fluoride-waste records. A paper ISO certificate cannot substitute for asset-specific evidence that the selected deoxyfluorination route is safely controlled.
3. Build a jurisdictional dossier: Maintain CAS and structural confirmation, inventory status, REACH/CLP and TSCA assessments, PFAS questionnaire responses, CoA methods, SDS history, origin, and end-use declarations. Update the dossier when route, impurity profile, tonnage, or destination changes.

VIII. Conclusion

4,4-Difluorocyclohexanecarboxylic acid occupies a valuable niche where compact three-dimensional design, metabolic blocking, and readily derivatized carboxylic-acid chemistry intersect. Its commercial opportunity is strongest for suppliers that can translate route-class fluorination expertise into reproducible impurity control, safe HF engineering, scalable isolation, and documentation appropriate to the customer's development stage.

For 2026 sourcing, buyers should treat PFAS-adjacent questions as a due-diligence workstream rather than a label. A defensible purchase combines exact substance identity, lifecycle and TFA-pathway assessment, jurisdictional inventory review, fit-for-purpose ICH controls, and resilient logistics. That evidence-based approach protects medicinal-chemistry flexibility while reducing regulatory, environmental, and continuity risk.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 4,4-Difluorocyclohexanecarboxylic acid Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 4,4-Difluorocyclohexanecarboxylic acid supply chain:

• China custom-synthesis cluster: Integrated fluorine-chemistry producers and CRO/CDMO sites support catalog, pilot, and multikilogram output. Buyers should distinguish trading listings from the actual fluorination site and audit waste permits, corrosion controls, analytical ownership, and change-notification discipline.
• India pharmaceutical-intermediate network: Process-development and GMP-capable CDMOs can connect route optimization with sponsor quality systems and export documentation. Qualification should focus on fluorination asset experience, impurity-reference capability, raw-material traceability, and campaign segregation.
• EU and US specialty ecosystem: Smaller fluorination specialists, medicinal-chemistry suppliers, and sponsor-proximate CDMOs provide rapid technical exchange, method development, and regulated-program support. Their role often includes final purification, release testing, secure inventory, and second-source risk mitigation.